Ann Dermatol.  2020 Feb;32(1):1-7. 10.5021/ad.2020.32.1.1.

Characteristics of Pruritus according to Morphological Phenotype of Psoriasis and Association with Neuropeptides and Interleukin-31

• Park SM
• Kim GW
• Kim HS
• Ko HC
• Kim MB
• Kim BS

• KMID: 2467194
• DOI: http://doi.org/10.5021/ad.2020.32.1.1

Abstract

BACKGROUND
Pruritus is a common symptom in psoriasis. However, few studies have assessed the characteristics of pruritus according to morphological phenotypes of psoriasis.
OBJECTIVE
To investigate the characteristics of pruritus according to morphological phenotypes of psoriasis and to assess the association with inflammatory mediators related to pruritus.
METHODS
Psoriasis patients were divided into 2 groups according to clinical phenotype: eruptive inflammatory (EI) and chronic stable (CS). Clinical data of pruritus were assessed by an itch questionnaire. Serum neuropeptides and cytokines including substance P, histamine, vasoactive intestinal peptide, neuropeptide Y, calcitonin gene-related peptide and interleukin-31 (IL-31) were quantitatively measured.
RESULTS
In total, 50 patients with psoriasis (30 male, 20 female; mean age, 45.7 years) were studied (EI, n=15 and CS, n=35). Pruritus was reported by 80% of EI and CS patients. There were no significant differences in prevalence of pruritus, pruritus intensity, severity of psoriasis, serum neuropeptides, or IL-31 between the 2 groups.
CONCLUSION
The morphological phenotype does not seem to be an important factor affecting the prevalence and characteristics of pruritus in psoriasis.

Keyword

Interleukin-31; Neuropeptide; Phenotype; Pruritus; Psoriasis

MeSH Terms

Calcitonin Gene-Related Peptide
Cytokines
Female
Histamine
Humans
Male
Neuropeptide Y
Neuropeptides*
Phenotype*
Prevalence
Pruritus*
Psoriasis*
Substance P
Vasoactive Intestinal Peptide
Calcitonin Gene-Related Peptide
Cytokines
Histamine
Neuropeptide Y
Neuropeptides
Substance P
Vasoactive Intestinal Peptide

Reference

1. Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008; 22:822–826.

2. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000; 143:969–973.

3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137:280–284.

4. Reich A, Szepietowski JC. Mediators of pruritus in psoriasis. Mediators Inflamm. 2007; 2007:64727.

5. Potenzieri C, Undem BJ. Basic mechanisms of itch. Clin Exp Allergy. 2012; 42:8–19.

6. Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007; 156:1272–1277.

7. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itchassociated cutaneous factors. Br J Dermatol. 2003; 149:718–730.

8. Amatya B, El-Nour H, Holst M, Theodorsson E, Nordlind K. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol. 2011; 164:1023–1029.

9. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol. 2011; 25:334–339.

10. Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol. 2006; 15:161–167.

11. Narbutt J, Olejniczak I, Sobolewska-Sztychny D, Sysa-Jedrzejowska A, Słowik-Kwiatkowska I, Hawro T, et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res. 2013; 305:191–195.

12. Choe YB, Hwang YJ, Hahn HJ, Jung JW, Jung HJ, Lee YW, et al. A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis. Br J Dermatol. 2012; 167:762–767.

13. Fitzpatrick TB, Gilchrest BA, Goldsmith LA, Katz SI, Paller AS, Leffell DJ, et al. Fitzpatrick's dermatology in general medicine. 8th ed. New York: McGraw-Hill Education;2012.

14. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004; 151:594–599.

15. Reich A, Orda A, Wiśnicka B, Szepietowski JC. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol. 2007; 16:421–428.

16. Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014; 70:390–391.

17. Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. Br J Dermatol. 2004; 151:1284.

18. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study. Clin Exp Dermatol. 1995; 20:384–389.

19. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. The role of neuropeptides in psoriasis. Br J Dermatol. 2006; 155:876–882.

20. Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol. 1990; 29:418–420.

21. Wiśnicka B, Szepietowski JC, Reich A, Orda A. Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis. Dermatol Psychosom. 2004; 5:73–78.

22. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006; 117:411–417.

23. Taneda K, Tominaga M, Negi O, Tengara S, Kamo A, Ogawa H, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol. 2011; 165:277–284.

24. Nigam R, El-Nour H, Amatya B, Nordlind K. GABA and GABA(A) receptor expression on immune cells in psoriasis: a pathophysiological role. Arch Dermatol Res. 2010; 302:507–515.

25. Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol. 2007; 21:72–78.

26. Takahashi H, Tsuji H, Minami-Hori M, Miyauchi Y, Iizuka H. Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol. 2014; 41:144–148.

27. Leon A, Rosen JD, Hashimoto T, Fostini AC, Paus R, Yosipovitch G. Itching for an answer: a review of potential mechanisms of scalp itch in psoriasis. Exp Dermatol. 2019; DOI: 10.1111/exd.13947. [Epub ahead of print].

28. Schönefuss A, Wendt W, Schattling B, Schulten R, Hoffmann K, Stuecker M, et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol. 2010; 19:e80–e88.

29. Scholzen TE, Luger TA. Neutral endopeptidase and angiotensin- converting enzyme -- key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol. 2004; 13 Suppl 4:22–26.

30. Youn SW, Choi CW, Kim BR, Chae JB. Reduction of interrater and intra-rater variability in psoriasis area and severity index assessment by photographic training. Ann Dermatol. 2015; 27:557–562.